CNCE Concert Pharmaceuticals Inc

2,119

$8.39

$0.025

(0.30%)

Today

Market Cap	$401.95M
52-Wk High	$8.55
52-Wk Low	$2.66

ST Data

Watchers

New Watcher Rank

Fundamentals

Concert Pharmaceuticals (NASDAQ:CNCE) Upgraded to "Hold" at StockNews.comZolmax • 9 months ago

StockNews.com upgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) from a sell rating to a hold rating in a report released on Saturday. Other research analysts have also issued research reports about the company. Truist Financial lowered Concert Pharmaceuticals from a buy rating to a...

Share to Feed

StockNews.com Upgrades Concert Pharmaceuticals (NASDAQ:CNCE) to "Hold"Ticker Report • 9 months ago

Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) was upgraded by research analysts at StockNews.com from a sell rating to a hold rating in a report issued on Saturday. CNCE has been the topic of a number of other reports. Truist Financial lowered shares of Concert...

Point72 Asset Management L.P. Invests $1.81 Million in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Zolmax • 9 months ago

Point72 Asset Management L.P. acquired a new position in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE Get Rating) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 270,600 shares of the ...

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Short Interest UpdateTicker Report • 9 months ago

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE Get Rating) saw a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,080,000 shares, a decline of 58.5% from the January 31st total of 2,600,000 shares. Based on an average daily ...

Concert Pharmaceuticals (NASDAQ:CNCE) Downgraded by StockNews.comTicker Report • 10 months ago

StockNews.com lowered shares of Concert Pharmaceuticals (NASDAQ:CNCE Get Rating) from a hold rating to a sell rating in a research note published on Friday. Several other research firms also recently issued reports on CNCE. Jonestrading reiterated a hold rating on shares of Concert ...

Concert Pharmaceuticals (NASDAQ:CNCE) Downgraded by StockNews.comZolmax • 10 months ago

Concert Pharmaceuticals (CNCE, $8.4) RSI Indicator left the overbought zone on February 22, 2023Tickeron - Technical Analysis • 10 months ago

This is a signal that CNCE's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Concert Pharmaceuticals (CNCE, $8.35) RSI Indicator left the overbought zone on February 21, 2023Tickeron - Stocks • 10 months ago

This is a signal that CNCE's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Insider Selling: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insider Sells $31,375.08 in StockTicker Report • 10 months ago

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE Get Rating) insider Jeffrey A. Munsie sold 3,762 shares of the businesss stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $8.34, for a total value of $31,375.08. Following the sale, ...

Nancy Stuart Sells 6,048 Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) StockTicker Report • 10 months ago

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE Get Rating) COO Nancy Stuart sold 6,048 shares of the firms stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $8.33, for a total transaction of $50,379.84. Following the sale, the chief operating...